Literature DB >> 25248574

Congenital GATA1-mutated myeloproliferative disorder in trisomy 21 complicated by placental fetal thrombotic vasculopathy.

Tracy J Z Loh1, Derrick W Q Lian2, Prasad Iyer3, Joyce C M Lam3, Chik H Kuick1, Aye C L Aung1, Kenneth Tou En Chang1.   

Abstract

Congenital myeloproliferative disorders and transient leukemic disorders have been described in the perinatal period in infants with trisomy 21 (Down syndrome). We report a novel case of a neonate with trisomy 21 with GATA1-mutated congenital myeloproliferative disorder complicated by placental fetal thrombotic vasculopathy featuring chorionic vessel leukemic thrombi, fetal circulation vascular injuries, and large aggregates of avascular villi. These thrombotic and vasculopathic changes within the placenta are likely a reflection of the hypercoagulable state caused by the myeloproliferative disorder. Placental fetal thrombotic vasculopathy is associated with adverse outcomes for the infant, and should be documented during formal pathological examination of the placenta.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Congenital myeloproli-ferative disorder; Fetal thrombotic vasculopathy; GATA1 mutation; Placental pathology; Trisomy 21 (Down syndrome)

Mesh:

Substances:

Year:  2014        PMID: 25248574     DOI: 10.1016/j.humpath.2014.07.019

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  2 in total

1.  Myeloid cell thrombus and fetal vascular malperfusion in placentas with transient abnormal myelopoiesis.

Authors:  Kayo Tomimori; Yuki Kodama; Hiroyuki Tanaka; Atushi Yamashita; Toshihiro Gi; Yujiro Asada; Koutarou Doi; Shinji Katsuragi; Yuichiro Sato
Journal:  Virchows Arch       Date:  2022-02-24       Impact factor: 4.064

2.  Progressive Venous Thrombosis in an 18-Year-Old Man with Down Syndrome.

Authors:  Yan Lin; Lin Ma; Wen-Jing Jiang; Yi-Ming Liu
Journal:  Chin Med J (Engl)       Date:  2018-10-20       Impact factor: 2.628

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.